MX2022002451A - Metodos para el tratamiento de la enfermedad cln2 en sujetos pediatricos. - Google Patents
Metodos para el tratamiento de la enfermedad cln2 en sujetos pediatricos.Info
- Publication number
- MX2022002451A MX2022002451A MX2022002451A MX2022002451A MX2022002451A MX 2022002451 A MX2022002451 A MX 2022002451A MX 2022002451 A MX2022002451 A MX 2022002451A MX 2022002451 A MX2022002451 A MX 2022002451A MX 2022002451 A MX2022002451 A MX 2022002451A
- Authority
- MX
- Mexico
- Prior art keywords
- subject
- methods
- cln2
- disease
- cln2 disease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts or implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/14—Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)
- C12Y304/14009—Tripeptidyl-peptidase I (3.4.14.9)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Inorganic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962893535P | 2019-08-29 | 2019-08-29 | |
| PCT/US2020/048704 WO2021042020A1 (en) | 2019-08-29 | 2020-08-31 | Methods for treating cln2 disease in pediatric subjects |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022002451A true MX2022002451A (es) | 2022-06-02 |
Family
ID=72470612
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022002451A MX2022002451A (es) | 2019-08-29 | 2020-08-31 | Metodos para el tratamiento de la enfermedad cln2 en sujetos pediatricos. |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20220273775A1 (https=) |
| EP (2) | EP4021575B1 (https=) |
| JP (2) | JP2022546042A (https=) |
| KR (1) | KR20220054375A (https=) |
| CN (1) | CN114828960A (https=) |
| AR (1) | AR119871A1 (https=) |
| AU (1) | AU2020336984B2 (https=) |
| BR (1) | BR112022003598A2 (https=) |
| CA (1) | CA3152521A1 (https=) |
| CL (1) | CL2022000496A1 (https=) |
| DK (1) | DK4021575T3 (https=) |
| ES (1) | ES2987156T3 (https=) |
| FI (1) | FI4021575T3 (https=) |
| HR (2) | HRP20240871T1 (https=) |
| HU (1) | HUE067135T2 (https=) |
| IL (1) | IL290763A (https=) |
| LT (1) | LT4021575T (https=) |
| MX (1) | MX2022002451A (https=) |
| PL (1) | PL4021575T3 (https=) |
| PT (1) | PT4021575T (https=) |
| RS (1) | RS65763B1 (https=) |
| SI (1) | SI4021575T1 (https=) |
| SM (1) | SMT202400315T1 (https=) |
| TW (1) | TW202122106A (https=) |
| WO (1) | WO2021042020A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220323019A1 (en) * | 2021-04-02 | 2022-10-13 | Neuropace, Inc. | Systems and methods for obtaining a clinical response estimate biomarker using machine-learned models trained on implanted neurostimulator data |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6302685B1 (en) | 1997-09-16 | 2001-10-16 | University Of Medicine And Dentistry Of New Jersey | Human lysosomal protein and methods of its use |
| US20020006400A1 (en) * | 2000-05-11 | 2002-01-17 | Peter Lobel | Recombinant human CLN2 protein and methods of its production and use |
| US7442372B2 (en) | 2003-08-29 | 2008-10-28 | Biomarin Pharmaceutical Inc. | Delivery of therapeutic compounds to the brain and other tissues |
| LT2588130T (lt) * | 2010-06-25 | 2016-12-12 | Shire Human Genetic Therapies, Inc. | Terapinės priemonės pristatymas cns |
| US20140377244A1 (en) | 2011-12-23 | 2014-12-25 | Shire Human Genetic Therapies, Inc. | Stable formulations for cns delivery of arylsulfatase a |
| TWI752907B (zh) * | 2015-05-08 | 2022-01-21 | 美商拜奧馬林製藥公司 | 用於治療cln2疾病之tpp1調配物及方法 |
| KR102738860B1 (ko) * | 2015-10-23 | 2024-12-04 | 유니버시티 오브 아이오와 리써치 파운데이션 | 리소좀 축적 질환 (lsd)을 갖는 포유동물의 치료 방법에 사용하기 위한 aav 입자를 포함하는 약제학적 조성물 |
| BR112021009370A2 (pt) * | 2018-11-14 | 2021-08-17 | Regenxbio Inc. | método de tratamento da doença de batten cln2, composição farmacêutica e kit |
-
2020
- 2020-08-31 PT PT207714080T patent/PT4021575T/pt unknown
- 2020-08-31 SM SM20240315T patent/SMT202400315T1/it unknown
- 2020-08-31 PL PL20771408.0T patent/PL4021575T3/pl unknown
- 2020-08-31 HU HUE20771408A patent/HUE067135T2/hu unknown
- 2020-08-31 AU AU2020336984A patent/AU2020336984B2/en active Active
- 2020-08-31 MX MX2022002451A patent/MX2022002451A/es unknown
- 2020-08-31 SI SI202030455T patent/SI4021575T1/sl unknown
- 2020-08-31 HR HRP20240871TT patent/HRP20240871T1/hr unknown
- 2020-08-31 FI FIEP20771408.0T patent/FI4021575T3/fi active
- 2020-08-31 EP EP20771408.0A patent/EP4021575B1/en active Active
- 2020-08-31 AR ARP200102442A patent/AR119871A1/es unknown
- 2020-08-31 LT LTEPPCT/US2020/048704T patent/LT4021575T/lt unknown
- 2020-08-31 DK DK20771408.0T patent/DK4021575T3/da active
- 2020-08-31 BR BR112022003598A patent/BR112022003598A2/pt unknown
- 2020-08-31 TW TW109129724A patent/TW202122106A/zh unknown
- 2020-08-31 CN CN202080068971.3A patent/CN114828960A/zh active Pending
- 2020-08-31 EP EP24177169.0A patent/EP4438120A3/en active Pending
- 2020-08-31 JP JP2022513165A patent/JP2022546042A/ja active Pending
- 2020-08-31 US US17/638,029 patent/US20220273775A1/en active Pending
- 2020-08-31 KR KR1020227010387A patent/KR20220054375A/ko active Pending
- 2020-08-31 HR HRP20220370AA patent/HRP20220370A1/hr not_active Application Discontinuation
- 2020-08-31 ES ES20771408T patent/ES2987156T3/es active Active
- 2020-08-31 CA CA3152521A patent/CA3152521A1/en active Pending
- 2020-08-31 WO PCT/US2020/048704 patent/WO2021042020A1/en not_active Ceased
- 2020-08-31 RS RS20240792A patent/RS65763B1/sr unknown
-
2022
- 2022-02-21 IL IL290763A patent/IL290763A/en unknown
- 2022-02-28 CL CL2022000496A patent/CL2022000496A1/es unknown
-
2025
- 2025-08-12 JP JP2025134120A patent/JP2025165414A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021042020A1 (en) | 2021-03-04 |
| RS65763B1 (sr) | 2024-08-30 |
| SI4021575T1 (sl) | 2024-10-30 |
| PT4021575T (pt) | 2024-07-30 |
| PL4021575T3 (pl) | 2024-09-23 |
| EP4438120A3 (en) | 2024-12-11 |
| BR112022003598A2 (pt) | 2022-05-24 |
| EP4021575B1 (en) | 2024-05-22 |
| HRP20220370A1 (hr) | 2022-09-16 |
| HRP20240871T1 (hr) | 2024-10-11 |
| TW202122106A (zh) | 2021-06-16 |
| ES2987156T3 (es) | 2024-11-14 |
| EP4438120A2 (en) | 2024-10-02 |
| LT4021575T (lt) | 2024-08-12 |
| IL290763A (en) | 2022-04-01 |
| AU2020336984A1 (en) | 2022-03-10 |
| AR119871A1 (es) | 2022-01-19 |
| CL2022000496A1 (es) | 2022-10-21 |
| JP2022546042A (ja) | 2022-11-02 |
| CA3152521A1 (en) | 2021-03-04 |
| FI4021575T3 (fi) | 2024-07-24 |
| HUE067135T2 (hu) | 2024-10-28 |
| SMT202400315T1 (it) | 2024-09-16 |
| DK4021575T3 (da) | 2024-08-05 |
| CN114828960A (zh) | 2022-07-29 |
| EP4021575A1 (en) | 2022-07-06 |
| KR20220054375A (ko) | 2022-05-02 |
| JP2025165414A (ja) | 2025-11-04 |
| AU2020336984B2 (en) | 2026-04-23 |
| US20220273775A1 (en) | 2022-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2020047462A3 (en) | Methods of treating aging-related disorders | |
| EP4327873A3 (en) | Tpp1 formulations and methods for treating cln2 disease | |
| BR112018013151A2 (pt) | alfa-glicosidase ácida aumentada para o tratamento da doença de pompe | |
| EA201190115A1 (ru) | Лечение расстройств, опосредованных нейротрофическим фактором | |
| Blanchard et al. | Management of somatic pain induced by head and neck cancer treatment: pain following radiation therapy and chemotherapy. Guidelines of the French Otorhinolaryngology Head and Neck Surgery Society (SFORL) | |
| WO2022047128A3 (en) | Method for treating complement mediated disorders caused by betacoronaviruses | |
| CL2022000496A1 (es) | Métodos para el tratamiento de la enfermedad cln2 en sujetos pediátrico | |
| BR112022009881A2 (pt) | Inibidores de caspase 6 e usos dos mesmos | |
| Artzi et al. | Fractional ablative CO2 laser followed by topical application of sodium stibogluconate for treatment of active cutaneous leishmaniasis: a randomized controlled trial | |
| Boyaci et al. | Comparison of the short-term effectiveness of short-wave diathermy treatment in patients with carpal tunnel syndrome: a randomized controlled trial | |
| WO2020061067A3 (en) | Compositions and methods for treating bone injury | |
| Karahan et al. | The effect of paraffin bath therapy versus extracorporeal shockwave therapy in the management of plantar fasciitis: A randomized clinical trial | |
| Poonsuk et al. | Comparing treatment efficacy of court-type traditional Thai massage, elastic taping, and stretching for plantar fasciitis: a three-armed randomized controlled trial | |
| RU2007120161A (ru) | Способ лечения больных остеоартрозом | |
| Ediriweera et al. | A clinical Study on effect of paste of Haritaki in Padadari (Cracked Feet) | |
| RU2835351C1 (ru) | Способ лечения онихомикоза методом фотодинамической терапии | |
| RU2566201C1 (ru) | Способ лечения витилиго | |
| RU2743166C2 (ru) | Косметический способ | |
| RU2488414C1 (ru) | Способ лечения профессионального миофиброза верхних конечностей | |
| Sabade et al. | The clinical study of the efficacy of Viddhagni Karma in the pain management of calcaneal spur | |
| WO2025264860A3 (en) | Methods of treating post-covid airway disease | |
| WO2024227085A3 (en) | Compounds and methods for treating human subjects | |
| Panchal et al. | A Single Case Study of Cupping Therapy in AVABAHUK (Frozen Shoulder). | |
| MX2022002947A (es) | Avocatina b para el tratamiento de enfermedades y afecciones. | |
| Iraji et al. | Research Article Microneedling in Combination with Topical Pimecrolimus 1% versus Topical Pimecrolimus 1% for the Treatment of Refractory Stable Vitiligo: A Randomized Clinical Trial |